Get the Stockscreener App
17.92
0.73%
0.13
Travere Therapeutics Inc stock is traded at $17.92, with a volume of 1.91M.
It is up +0.73% in the last 24 hours and up +14.43% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$17.79
Open:
$17.82
24h Volume:
1.91M
Relative Volume:
1.22
Market Cap:
$1.60B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-8.7843
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
-4.78%
1M Performance:
+14.43%
6M Performance:
-18.47%
1Y Performance:
+109.10%
1-Day Range:
$17.71
$18.37
1-Week Range:
$17.24
$19.08
52-Week Range:
$8.50
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
17.92 | 1.67B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere therapeutics executive sells shares worth $106,081 - MSN
Technical Models Suggest Travere Therapeutics Inc. May Rebound Soon - beatles.ru
Strategic Positioning and Growth Potential Drive Buy Rating for Travere Therapeutics - TipRanks
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN
Travere Therapeutics Inc. Charts Flash Early Recovery SignalsJuly 2025 Levels & Technical Buy Zone Confirmation - metal.it
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Wall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to Buy - Defense World
How high can Travere Therapeutics Inc. stock goWeekly Trend Recap & High Conviction Buy Zone Picks - Newser
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc.Market Sentiment Report & Real-Time Volume Analysis Alerts - sundaytimes.kr
Is Travere Therapeutics Inc.’s growth already priced inWeekly Trade Summary & Free Safe Capital Growth Stock Tips - thegnnews.com
Multi asset correlation models including Travere Therapeutics Inc.2025 Key Highlights & Weekly High Return Opportunities - Newser
Key metrics from Travere Therapeutics Inc.’s quarterly dataJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Analysts' Top Picks in Healthcare: Merus, AdaptHealth, and Travere Therapeutics - AInvest
Why Travere Therapeutics Inc. is moving todayWeekly Profit Report & Reliable Volume Spike Trade Alerts - Newser
Visualizing Travere Therapeutics Inc. stock with heatmaps2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Travere Therapeutics at Canaccord Genuity: Strategic Insights from Growth Conference - Investing.com Canada
Travere Therapeutics Receives Positive Growth Outlook from Analysts Amid Filspari's Promising Market Potential and Strategic Initiatives - AInvest
Travere Therapeutics Approves Inducement Equity Grants for New Employees - AInvest
Trendlines Converge — Decision Point for Travere Therapeutics Inc.Earnings Performance Report & Entry Point Confirmation Alerts - beatles.ru
Why Travere Therapeutics Inc. stock attracts strong analyst attention2025 Year in Review & Long-Term Capital Growth Ideas - Newser
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc. [Weekly Risk Report]Free Verified Swing Trading Watchlist - 선데이타임즈
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript - MSN
Travere Therapeutics Sees Promising Growth with FILSPARI - AInvest
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Travere Therapeutics (TVTX) Is Up 8.3% After Revenue Jump and Narrower Losses in Q2 – What's Changed - simplywall.st
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics price target raised to $34 from $32 at Citi - MSN
Visual analytics tools that track Travere Therapeutics Inc. performanceFree Low Drawdown Real Time Trading Tips - Newser
Travere Therapeutics Earnings Call Highlights FILSPARI Success - TipRanks
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $32.00 - Defense World
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00 - Defense World
Travere Therapeutics Reports Strong Q2 2025 Growth - MSN
Travere Therapeutics price target raised to $32 from $30 at Wedbush - Yahoo Finance
Travere Therapeutics shares fall 5.16% intraday despite positive earnings report and price target increase. - AInvest
Scotiabank Raises Price Target for Travere Therapeutics (TVTX) t - GuruFocus
Travere Therapeutics: Scotiabank maintains Sector Outperform, PT raised to $31 from $30. - AInvest
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability - simplywall.st
Travere Therapeutics price target raised to $31 from $30 at Scotiabank - TipRanks
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty - Investing.com
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty By Investing.com - Investing.com South Africa
Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating - MarketScreener
TVTX: Wedbush Raises Price Target and Maintains Outperform Ratin - GuruFocus
Travere: Q2 Earnings Snapshot - Huron Daily Tribune
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications - MSN
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts - Investing.com
Travere Therapeutics Reports Second Quarter 2025 Financial Results - BioSpace
Travere Therapeutics: Scaling the Rare Disease Ladder—Can FILSPARI Sustain Its Momentum? - AInvest
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics - AInvest
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Travere Therapeutics Inc Stock (TVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,784 |
37,553 |
93,126 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):